Clinical Trial Search

Primary: Number of Local and Systemic Adverse Events (AEs) to Assess the Safety of the Study Drug — 34; 24; 23; 16 Adverse Events

Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns

Primary: Self-reported HIV or STI Testing in Past 3 Months — 76; 88 Participants — p=0.914

Primary: Area Under the Plasma Concentration-time Profile From Time 0 the Last Quantifiable Concentration (AUC0-last) With Dose Normalization — 658; 700; 716; 748 pg.h/mL…

Primary: Percentage of Pregnancies Prevented — 94.7; 63.3 percentage of pregnancies prevented — p=<0.0001

Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)

Primary: Percentage of Participants Who Converted From Atrial Fibrillation (AF) Within 90 Minutes From Start of Infusion and Subsequently Had no AF Recurrence Within 1 Minute of…

Primary: Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE, MoCA) and Brain Activity Features Extracted Using the Neurosteer…

Primary: ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases — 49; 49 ACTs

Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02

Primary: Focus Group Analysis (Aim I) — 43 Participants

Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01

Primary: Flu Vaccination — 4459; 4456; 4575 Participants — p=0.517

Primary: Number of Patients With Each Response as Measured by RECIST 1.1 — 0; 4; 2; 5 Participants

Primary: Mean Temperature Change- Skin Evaluation on Leg With Device — 6.21 degrees